Middle East Pharmaceutical Industries Company
Middle East Pharmaceutical Industries Company (4016.SR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
4016.sr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Middle East Pharmaceutical Industries Company (4016.SR) measures how much investors pay for each dollar of the company's trailing earnings. 4016.SR's current PE ratio of 20.87x is calculated by dividing its stock price of $62.10 by its TTM earnings per share of $2.97. −35.8% discount vs 5Y avg 32.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2019 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 7 fiscal years · Front-end computedMinQ1 · 25%32.4x
MedianQ3 · 75%39.4x
Max
At 20.87x, 4016.SR's current P/E is lower than in 0% of its annual fiscal year readings over the past 7 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Middle East Pharmaceutical Industries CompanyYou 4016.SR | $2.2B | 20.87x | -13.8% | $2.97 |
 Saudi Pharmaceutical Industries and Medical Appliances Corporation 2070.SR | $3.4B | 16.92x | -30.1% | $1.54 |
 Middle East Healthcare Company 4009.SR | $3.0B | 9.93x | -59.0% | $3.28 |
 Scientific and Medical Equipment House Company 4014.SR | $945M | 33.39x | +37.9% | $0.95 |
 Al-Dawaa Medical Services Company 4163.SR | $3.7B | 13.17x | -45.6% | $3.79 |
 Canadian General Medical Center Complex Company 9518.SR | $697M | 52.86x | +118.3% | $0.13 |
 Ame Company For Medical Supplies 9527.SR | $511M | 19.00x | -21.5% | $5.00 |
Industry Average 6 peers with valid PE | — | 24.21x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 22.93x | $2.77 | -41.5% | |
2024-12-31 FY2024 | 39.16x | $1.78 | +20.9% | |
2023-12-31 FY2023 | 32.39x | $1.88 | -9.7% | |
2022-12-31 FY2022 | 35.86x | $1.70 | +11.5% | |
2021-12-31 FY2021 | 32.16x | $1.89 | +9.9% | |
2020-12-31 FY2020 | 29.28x | $2.08 | -25.8% | |
2019-12-31 FY2019 | 39.44x | $1.54 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Middle East Pharmaceutical Industries Company (4016.SR) measures how much investors pay for each dollar of the company's trailing earnings. 4016.SR's current PE ratio of 20.87x is calculated by dividing its stock price of $62.10 by its TTM earnings per share of $2.97.
Frequently asked questions
4016.SR pe ratio · 6 questions4016.SR's current PE ratio is 20.87x as of 2026-06-16, based on a stock price of $62.10 and TTM EPS of $2.97. Data sourced from Financial Modeling Prep via 4016.SR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Middle East Pharmaceutical Industries Company SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-16